vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and KAISER ALUMINUM CORP (KALU). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $929.0M, roughly 1.0× KAISER ALUMINUM CORP). KAISER ALUMINUM CORP runs the higher net margin — 3.0% vs 0.7%, a 2.3% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 21.4%). Astrana Health, Inc. produced more free cash flow last quarter ($-6.0M vs $-51.1M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 12.2%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Kaiser Aluminum Corporation is an American aluminum producer. It is a spinoff from Kaiser Aluminum and Chemicals Corporation, which came to be when common stock was offered in Permanente Metals Corporation and Permanente Metals Corporation's name was changed to Kaiser Aluminum and Chemicals Corporation.

ASTH vs KALU — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.0× larger
ASTH
$950.5M
$929.0M
KALU
Growing faster (revenue YoY)
ASTH
ASTH
+21.5% gap
ASTH
42.9%
21.4%
KALU
Higher net margin
KALU
KALU
2.3% more per $
KALU
3.0%
0.7%
ASTH
More free cash flow
ASTH
ASTH
$45.1M more FCF
ASTH
$-6.0M
$-51.1M
KALU
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
12.2%
KALU

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
KALU
KALU
Revenue
$950.5M
$929.0M
Net Profit
$6.6M
$28.2M
Gross Margin
13.3%
Operating Margin
1.9%
6.5%
Net Margin
0.7%
3.0%
Revenue YoY
42.9%
21.4%
Net Profit YoY
184.4%
42.4%
EPS (diluted)
$0.12
$1.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
KALU
KALU
Q4 25
$950.5M
$929.0M
Q3 25
$956.0M
$843.5M
Q2 25
$654.8M
$823.1M
Q1 25
$620.4M
$777.4M
Q4 24
$665.2M
$765.4M
Q3 24
$478.7M
$747.7M
Q2 24
$486.3M
$773.4M
Q1 24
$404.4M
$737.5M
Net Profit
ASTH
ASTH
KALU
KALU
Q4 25
$6.6M
$28.2M
Q3 25
$373.0K
$39.5M
Q2 25
$9.4M
$23.2M
Q1 25
$6.7M
$21.6M
Q4 24
$-7.8M
$19.8M
Q3 24
$16.1M
$8.8M
Q2 24
$19.2M
$18.9M
Q1 24
$14.8M
$18.2M
Gross Margin
ASTH
ASTH
KALU
KALU
Q4 25
13.3%
Q3 25
13.6%
Q2 25
12.2%
Q1 25
13.4%
Q4 24
12.5%
Q3 24
9.6%
Q2 24
13.4%
Q1 24
11.7%
Operating Margin
ASTH
ASTH
KALU
KALU
Q4 25
1.9%
6.5%
Q3 25
2.0%
5.8%
Q2 25
3.1%
4.6%
Q1 25
3.3%
5.3%
Q4 24
0.1%
5.0%
Q3 24
5.9%
1.8%
Q2 24
6.2%
4.7%
Q1 24
7.5%
3.3%
Net Margin
ASTH
ASTH
KALU
KALU
Q4 25
0.7%
3.0%
Q3 25
0.0%
4.7%
Q2 25
1.4%
2.8%
Q1 25
1.1%
2.8%
Q4 24
-1.2%
2.6%
Q3 24
3.4%
1.2%
Q2 24
3.9%
2.4%
Q1 24
3.7%
2.5%
EPS (diluted)
ASTH
ASTH
KALU
KALU
Q4 25
$0.12
$1.67
Q3 25
$0.01
$2.38
Q2 25
$0.19
$1.41
Q1 25
$0.14
$1.31
Q4 24
$-0.14
$1.21
Q3 24
$0.33
$0.54
Q2 24
$0.40
$1.15
Q1 24
$0.31
$1.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
KALU
KALU
Cash + ST InvestmentsLiquidity on hand
$429.5M
$7.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$826.1M
Total Assets
$2.2B
$2.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
KALU
KALU
Q4 25
$429.5M
$7.0M
Q3 25
$463.4M
$17.2M
Q2 25
$342.1M
$13.1M
Q1 25
$260.9M
$21.3M
Q4 24
$290.8M
$18.4M
Q3 24
$350.3M
$45.7M
Q2 24
$327.7M
$70.4M
Q1 24
$337.3M
$101.6M
Stockholders' Equity
ASTH
ASTH
KALU
KALU
Q4 25
$779.3M
$826.1M
Q3 25
$775.5M
$806.1M
Q2 25
$765.5M
$776.0M
Q1 25
$745.4M
$756.8M
Q4 24
$712.7M
$743.1M
Q3 24
$704.6M
$729.4M
Q2 24
$678.9M
$727.6M
Q1 24
$653.5M
$714.7M
Total Assets
ASTH
ASTH
KALU
KALU
Q4 25
$2.2B
$2.6B
Q3 25
$2.2B
$2.6B
Q2 25
$1.4B
$2.5B
Q1 25
$1.3B
$2.4B
Q4 24
$1.4B
$2.4B
Q3 24
$1.3B
$2.3B
Q2 24
$1.3B
$2.3B
Q1 24
$1.2B
$2.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
KALU
KALU
Operating Cash FlowLast quarter
$-2.9M
$-20.6M
Free Cash FlowOCF − Capex
$-6.0M
$-51.1M
FCF MarginFCF / Revenue
-0.6%
-5.5%
Capex IntensityCapex / Revenue
0.3%
3.3%
Cash ConversionOCF / Net Profit
-0.44×
-0.73×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$-25.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
KALU
KALU
Q4 25
$-2.9M
$-20.6M
Q3 25
$10.0M
$59.1M
Q2 25
$90.9M
$15.9M
Q1 25
$16.6M
$57.0M
Q4 24
$-10.9M
$43.4M
Q3 24
$34.0M
$34.1M
Q2 24
$23.2M
$26.3M
Q1 24
$6.0M
$63.3M
Free Cash Flow
ASTH
ASTH
KALU
KALU
Q4 25
$-6.0M
$-51.1M
Q3 25
$7.4M
$34.5M
Q2 25
$89.5M
$-27.7M
Q1 25
$13.6M
$18.8M
Q4 24
$-13.5M
$-12.6M
Q3 24
$31.7M
$-17.0M
Q2 24
$20.4M
$-17.4M
Q1 24
$5.6M
$33.3M
FCF Margin
ASTH
ASTH
KALU
KALU
Q4 25
-0.6%
-5.5%
Q3 25
0.8%
4.1%
Q2 25
13.7%
-3.4%
Q1 25
2.2%
2.4%
Q4 24
-2.0%
-1.6%
Q3 24
6.6%
-2.3%
Q2 24
4.2%
-2.2%
Q1 24
1.4%
4.5%
Capex Intensity
ASTH
ASTH
KALU
KALU
Q4 25
0.3%
3.3%
Q3 25
0.3%
2.9%
Q2 25
0.2%
5.3%
Q1 25
0.5%
4.9%
Q4 24
0.4%
7.3%
Q3 24
0.5%
6.8%
Q2 24
0.6%
5.7%
Q1 24
0.1%
4.1%
Cash Conversion
ASTH
ASTH
KALU
KALU
Q4 25
-0.44×
-0.73×
Q3 25
26.69×
1.50×
Q2 25
9.65×
0.69×
Q1 25
2.48×
2.64×
Q4 24
2.19×
Q3 24
2.11×
3.88×
Q2 24
1.21×
1.39×
Q1 24
0.40×
3.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

KALU
KALU

Packaging$440.6M47%
Aero Hs Products$213.0M23%
Transferred Over Time$200.2M22%
Automotive Extrusions$75.4M8%

Related Comparisons